Brokerages Set Artelo Biosciences, Inc. (NASDAQ:ARTL) PT at $24.00

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have earned an average rating of “Hold” from the six ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $24.00.

Several research analysts have weighed in on ARTL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a research note on Tuesday, November 11th. D. Boral Capital restated a “hold” rating on shares of Artelo Biosciences in a report on Monday, September 8th. Maxim Group reaffirmed a “hold” rating on shares of Artelo Biosciences in a research note on Wednesday. Wall Street Zen cut Artelo Biosciences to a “strong sell” rating in a research report on Saturday, August 9th. Finally, D Boral Capital downgraded Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th.

Artelo Biosciences Trading Down 2.1%

Shares of Artelo Biosciences stock opened at $1.85 on Monday. Artelo Biosciences has a 1 year low of $1.66 and a 1 year high of $28.60. The company has a market cap of $1.30 million, a P/E ratio of -0.09 and a beta of 1.23. The stock has a 50-day moving average price of $3.88 and a 200 day moving average price of $7.37.

Artelo Biosciences (NASDAQ:ARTL) last issued its earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). On average, equities analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.